Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients ; volume:14 ; number:1 ; day:29 ; month:10 ; year:2024 ; pages:1-7 ; date:12.2024
Scientific reports ; 14, Heft 1 (29.10.2024), 1-7, 12.2024
- Urheber
-
Saheb Sharif-Askari, Fatemeh
Ali Hussain Alsayed, Hawra
Saheb Sharif-Askari, Narjes
Al Sayed Hussain, Ali
Al-Muhsen, Saleh
Halwani, Rabih
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-76472-0
- URN
-
urn:nbn:de:101:1-2501182102190.663243000431
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saheb Sharif-Askari, Fatemeh
- Ali Hussain Alsayed, Hawra
- Saheb Sharif-Askari, Narjes
- Al Sayed Hussain, Ali
- Al-Muhsen, Saleh
- Halwani, Rabih
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nirmatrelvir plus ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization
Clinical characteristics of current COVID-19 rehabilitation outpatients in China
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
Hospitalization budget impact during the COVID-19 pandemic in Spain
Hospitalization patterns for adolescents with eating disorders during COVID-19
Nirmatrelvir plus ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization
Clinical characteristics of current COVID-19 rehabilitation outpatients in China
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
Hospitalization budget impact during the COVID-19 pandemic in Spain
Hospitalization patterns for adolescents with eating disorders during COVID-19
Nirmatrelvir plus ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Nirmatrelvir/Ritonavir (COVID-19) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization
Clinical characteristics of current COVID-19 rehabilitation outpatients in China
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
Hospitalization budget impact during the COVID-19 pandemic in Spain